-
Recent Posts
- Dementia and Disability (APPG on Dementia / Alzheimer’s Society)
- Scoping Dimensions of Dementia-Friendly Organisations (JGCR / IES / Alzheimer’s Society / RCN / JRF)
- Facts and Figures on Unmet Needs in Older People in England (Age UK)
- Statistics on Unpaid Carers in the UK: Carers Rights Day 2019 (Carers UK)
- Dementia Risk Factors Re-Explored / Confirmed (NIHR Signal / BMJ Open)
Archives
- December 2019
- November 2019
- October 2019
- September 2019
- August 2019
- July 2019
- June 2019
- May 2019
- April 2019
- March 2019
- February 2019
- January 2019
- December 2018
- November 2018
- October 2018
- September 2018
- August 2018
- July 2018
- June 2018
- May 2018
- April 2018
- March 2018
- February 2018
- January 2018
- December 2017
- November 2017
- October 2017
- September 2017
- August 2017
- July 2017
- June 2017
- May 2017
- April 2017
- March 2017
- February 2017
- January 2017
- December 2016
- November 2016
- October 2016
- September 2016
- August 2016
- July 2016
- June 2016
- May 2016
- April 2016
- March 2016
- February 2016
- January 2016
- December 2015
- November 2015
- October 2015
- September 2015
- August 2015
- July 2015
- June 2015
- May 2015
- April 2015
- March 2015
- February 2015
- January 2015
- December 2014
- November 2014
- October 2014
- September 2014
- August 2014
- July 2014
- June 2014
- May 2014
- April 2014
- March 2014
- February 2014
- January 2014
- December 2013
- November 2013
- October 2013
- September 2013
- August 2013
- July 2013
- June 2013
- May 2013
- April 2013
- March 2013
- February 2013
- January 2013
- December 2012
- November 2012
- October 2012
- September 2012
- August 2012
- July 2012
- June 2012
- May 2012
- April 2012
- March 2012
- February 2012
- January 2012
- December 2011
- November 2011
- October 2011
- September 2011
- August 2011
- July 2011
- June 2011
- May 2011
- April 2011
- March 2011
- February 2011
- January 2011
- December 2010
- November 2010
Categories
- Antipsychotics
- Assistive Technology
- Charitable Bodies
- Commissioning
- Delirium
- Depression
- Enhancing the Healing Environment
- Falls
- Falls Prevention
- Guidelines
- Hip Fractures
- Housing
- Hypertension
- In the News
- Integrated Care
- International
- Local Interest
- Mental Health
- Models of Dementia Care
- National
- ADASS
- All-Party Parliamentary Group (APPG) on Dementia
- BSI
- CQC: Care Quality Commission
- Department of Health
- Department of Health and Social Care (DHSC)
- Health Education England (HEE)
- Housing LIN
- MAGDR
- Mental Health Foundation
- Mental Health Network (NHS Confederation)
- MHP Health Mandate
- National Audit Office
- National Voices
- NEoLCIN
- NEoLCP
- NHS
- NHS Alliance
- NHS Confederation
- NHS Employers
- NHS England
- NHS Evidence
- NHS Improvement
- NICE Guidelines
- NIHR
- NIHRSDO
- Northern Ireland
- Patients Association
- Public Health England
- RCN
- Royal College of Physicians
- Royal College of Psychiatrists
- SCIE
- Scotland
- UK
- UK NSC
- Wales
- Non-Pharmacological Treatments
- Nutrition
- Pain
- Parkinson's Disease
- Patient Care Pathway
- Person-Centred Care
- Personalisation
- Pharmacological Treatments
- Proposed for Next Newsletter
- Quick Insights
- Standards
- Statistics
- Stroke
- Systematic Reviews
- Telecare
- Telehealth
- Universal Interest
Google Translate (100+ Languages)
Tag Archives: Drug Development for Alzheimer’s Disease
Blood Test Able to Predict Alzheimer’s Disease Decades Before Symptoms? (BBC News / Neurology)
Summary Research published in the Neurology journal claims a significant breakthrough in the development of a blood test (for plasma Aβ42/Aβ40) which may be able to predict Alzheimer’s Disease onset with 94% accuracy. Due caution: “But it’s important to note … Continue reading →
Posted in BBC News, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Quick Insights, Universal Interest
|
Tagged Alzheimer's Disease: Diagnosis, Alzheimer’s Early Screening, Amyloid, Amyloid and Tau PET, Amyloid Beta, Amyloid Beta (Aβ42 and Aβ40), Amyloid Beta Protein, Amyloid-β (Aβ), Amyloid-β Protein, BBC Health News, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood Proteins as Biomarkers of Disease Research, Blood Test for Brain Amyloidosis: Validated Using Amyloid PET and CSF p-tau181/Aβ42 as Reference Standards, Blood Tests, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, Brain Imaging, Brain Research, Case Finding, Conversion to Dementia From Prodromal Disease, Dementia Diagnosis, Dementia Innovation, Dementia Research, Dementia Screening, Department of Neurology: Washington University, Diagnosis, Diagnosis of Alzheimer's Disease, Diagnostic Imaging, Division of Biostatistics: Washington University, Drug Development for Alzheimer's Disease, Early Detection of Preclinical Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Hope Center for Neurological Disorders: Washington University, Knight Alzheimer's Disease Research Center: Washington University, Mallinckrodt Institute of Radiology: Washington University, Neurology (Journal), Non-Invasive Biomarkers, Plasma Biomarkers, Plasma β-Amyloid 42/40, Plasma Protein Markers of MRI Measures in Asymptomatic Individuals, Preclinical Alzheimer's Disease, Preclinical Biomarkers in Alzheimer's Disease, Predictive Ability (of Tests), Prodromal Alzheimer's Disease, Protein-Based Biomarkers in Blood May Deliver Accurate Diagnoses, Rapid Screening, Recruitment Onto Dementia Clinical Trials, SAP (Protein), SAP: Serum Amyloid Protein, Screening, Screening for Dementia, Washington University School of Medicine
|
Leave a comment
Summary of Recent Progress in Alzheimer’s Disease Prevention Trials (CTAD / JPAD)
Summary The following article summarises a round-up of present understanding and developments reflected in current and planned prevention trials, as discussed at a EU / US / Clinical Trials in Alzheimer’s Disease (CTAD) Task Force meeting, as of December 2016-7. … Continue reading →
Posted in For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Quick Insights
|
Tagged Accelerating Alzheimer's Research and Drug Development, Alzheimer's Disease Co-operative Study - Activities of Daily Living Scale (ADCS-ADL), Alzheimer’s Disease Prevention Trials, Alzheimer’s Prevention Initiative (API), Alzheimer’s Prevention Initiative Study, Alzheimer’s Therapeutic Research Institute (ATRI), Amsterdam IADL Questionnaire, Amyloid and Tau Imaging, Amyloid and Tau PET, Anti-Amyloid Treatment in Asymptomatic Alzheimer’s (A4) Study, Banner Alzheimer's Institute (Arizona), Biological Markers, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood Proteins as Biomarkers of Disease Research, Blood-Based Biomarkers, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, Brigham and Women's Hospital, Canada, CHU Toulouse (France), Cognitive Function Instrument, Cognitive Outcome Measures, Cogstate iPad C3 Battery, Collaboration for Alzheimer’s Prevention (CAP), Composite Measures (sic Cognitive Composites), Conversion to Dementia From Prodromal Disease, Dementia Prevention, Dementia Research and Drug Development, Dementia Risk Prevention, Dementia Risk Reduction and Prevention, Denali Therapeutics (South San Francisco), Department of Epidemiology and Public Health: CHU Toulouse, DIAN-TU Study, DIAN-TU Trial, Dominantly Inherited Alzheimer Network Trials Unit (DIAN-TU), Dominantly Inherited Alzheimer’s Network Trials Unit (DIAN-TU), Drug Development for Alzheimer's Disease, Drug-Development Pipeline, EU/US/Clinical Trials in Alzheimer's Disease (CTAD) Task Force, EU/US/Clinical Trials in Alzheimer's Disease (CTAD) Task Force (December 2016 Meeting), European Medicines Agency, Everyday Cognition (E-Cog) Scale, F-31073 (Toulouse), F. Hoffmann-LaRoche Ltd (Basel), France, Free and Cued Selective Reminding Test (FCSRT), Functional Activities Questionnaire (FAQ), Gerontopole Toulouse: Toulouse University Hospital, Global R&D Partners LLC (San Diego), Harvard Medical School, Imaging, Inc. (New York), Informant-Reported Outcome Measures, Innovation Infrastructure, Johns Hopkins University School of Medicine Baltimore, Journal of Prevention of Alzheimer’s Disease (JPAD), Keck School of Medicine: University of Southern California, Longitudinal Evaluation of Amyloid Risk and Neurodegeneration (LEARN) Study, McGill University, Molecular Imaging; Mild Behavioral Impairment, Multi-Domain Alzheimer’s Prevention Trial (MAPT), National Institutes of Health’s Accelerating Medicines Partnership (AMP), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurodegenerative Disorders, Neurodegenerative Research, Neurology (FDA), Next Generation (NexGen) Prevention Trial, NIH Toolbox Cognition Battery (NIHTB-CB), Non-Invasive Biomarkers, Outcome Measures, Participation in Research, Patient Reported Outcome Measures, Pentara Corporation (Salt Lake City), PET, Pfizer, Plasma Biomarkers, Preclinical Alzheimer's Disease, Preclinical Alzheimer’s Cognitive Composite (PACC), Preclinical Biomarkers and Dementia, Preclinical Biomarkers in Alzheimer's Disease, Preclinical Indicators and Dementia, Preclinical Indicators in Alzheimer's Disease, Prevention, Prevention Agenda, Prevention Agenda Linking Dementia and Other Non-Communicable Diseases, Prevention Approaches, Prodromal Alzheimer's Disease, Promisary Science, Recruitment and Retention, Regulation and Drug Development For Early-Stage Alzheimer's Disease, Research and Development, Research and Innovation, Research Commitment, Research Culture, Research Mapping, Research Networks, Research Promotion, Sharing Knowledge and Information, Slowing Progression of Disease (Stabilisation), Switzerland, Tau PET, Technology and Infrastructure Development, TOMMORROW Study, UMR1027 Inserm, United States, University College London, University Hospital of Montpellier, University of Southern California, University of Toulouse III, USA, Washington University School of Medicine
|
Leave a comment
AAIC’s Curated Round-Up of Publications Related to the 2016 Alzheimer’s Association International Conference (Alzheimer’s Association International Conference / Alzheimer’s and Dementia)
Summary Not everyone will have been able to attend the Alzheimer’s Association International Conference in Toronto last week. The Alzheimer’s Association AAIC Press Office has been kind enough to provide a curated collection of associated publications, relating to the 2016 … Continue reading →
Posted in Charitable Bodies, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Mental Health, Models of Dementia Care, Non-Pharmacological Treatments, Person-Centred Care, Pharmacological Treatments, Quick Insights, Universal Interest
|
Tagged 2016 Alzheimer’s Association International Conference (AAIC®2016), Aboriginal and Torres Strait Islanders, Accelerating Medicines Partnership (AMP-AD), AD Genetics Consortium (ADGC), AddNeuroMed, ADNI Depression Study, Advanced Cognitive Training for Independent and Vital Elderly (ACTIVE) Study, Alzheimer's and Dementia: The Journal of the Alzheimer's Association, Alzheimer's Association International Society to Advance Alzheimer's Research and Treatment (ISTAART), Alzheimer's Disease Big Data DREAM Challenge 1, Alzheimer's Disease Neuroimaging Initiative, Alzheimer’s Association, Alzheimer’s Association International Conference® (AAIC®) 2016, Alzheimer’s Disease Neuroimaging Initiative (ADNI), Alzheimer’s Therapy Clinical Trial Results, Alzheimers and Dementia, Argentina ADNI (Arg-ADNI), Australian ADNI, Australian Imaging Biomarkers and Lifestyle Study of Aging (AIBL), Avoidable Hospital Admissions, Avoidable Hospitalizations of People With Alzheimer’s Disease: Cost to Medicare (USA), Behavioural and Psychological Symptoms of Dementia (BPSD), Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Brain Insulin and Insulin Receptors, Brain Insulin Resistance, Caregiver Burden and Dependence, Causes of Brain Insulin Resistance, China ADNI (C-ADNI), Chronic Traumatic Brain Injury, Clinical Dementia Rating–Sum of Boxes (CDR-SB), Cognitive Training, Critical Path Institute's (C-Path) Coalition Against Major Diseases (CAMD) Initiative, CSF Biomarkers, DADE Investigator Group, DADE Study, Dementia-Related Misdiagnosis, Dementia-Related Misdiagnosis (Male), Department of Defense Alzheimer's Disease Neuroimaging Initiative, Dependence in AD in England (DADE), Dependence Scale (DS), Dialogue on Reverse Engineering Assessment and Methods (DREAM) Project, Dietary Recommendations, Disease Modification, Down Syndrome Biomarker Initiative, DREAM, Drug Development for Alzheimer's Disease, Early Treatment to Reduce Costs and Mortality, EPAD, Estrogen Receptor (ESR), Estrogen Receptor Polymorphisms and Incident Dementia, European ADNI (E-ADNI), European Medical Information Framework (EMIF), Food and Drug Administration (FDA)'s Guidance for Industry Alzheimer’s Disease: Developing Drugs for the Treatment of Early Stage Disease, Formal Education and Complex Work, Framingham Heart Study, Frontotemporal Lobar Degeneration Neuroimaging Initiative, Genetic and Environmental Risk for AD Consortium (GERAD1), Global CEO Initiative for Alzheimer's Disease, Glucagon-Like Peptide-1 (GLP-1) Analogs, Imatinib Inhibition of Amyloid Precursor Protein (APP) In Humans, Imatinib Treatment and Aβ42 (In Humans), Impacts of ADNI, Incretin Mimetics, Innovative Medicine Initiative AD Research Platform, Insulin Receptor Substrate-1 (IRS-1) Signaling Pathway, Italo Monzino Foundation, Japanese ADNI (J-ADNI), Korean ADNI, Laboratory of Neuroimaging (LONI), Leuco-Methylthioninium (LMTM), Liraglutide (Victoza), LMTM Monotherapy, MBI Checklist (MBI-C), Mediterranean and DASH Diets, Mediterranean Diet, Mediterranean-DASH Intervention for Neurodegenerative Delay: MIND, Mediterranean-Dietary Approach to Systolic Hypertension (DASH) Diet, Mediterranean-Dietary Approach to Systolic Hypertension (DASH) Diet Intervention for Neurodegenerative Delay (MIND) Diet Score, Mild Behavioural Impairment (MBI), Mild Cognitive Impairment (MCI), MIND Diet, Monzino, Monzino 80-Plus Study, Neurodegeneration, Neurodegenerative Disease Research, North American Registry for Care and Research in MS, NPS Professional Interest Area (PIA), Parkinson's Progressive Markers Initiative (PPMI), Preclinical Alzheimer's Disease, Prevalence of Dementia in Aboriginal Australians, Prevalence of Dementia in China, Prevalence of Dementia in Oldest Old, Prodromal Alzheimer's Disease, Psychological Symptoms of Dementia (BPSD), Reduction of Systematic Sedation in Dementia Care, Regulation and Drug Development For Early-Stage Alzheimer's Disease, Relationship Between Age and Dementia Prevalence, Research and Development, Research and Innovation, Research Commitment, Resilience, Rush University Medical Center, Sage Bionetworks, Smell Tests For Detection of Memory Decline and Dementia, Streptozotocin (STZ), Taiwan ADNI, TauRx Therapeutics, Toronto, Transforming Research and Clinical Knowledge in Huntington's Disease (TRACK-HD), Translational Research, Translational Research Into Alzheimer's Disease in Europe, Traumatic Brain Injury, Traumatic Brain Injury (TBI), Treating Brain Insulin Resistance, Update of the Alzheimer's Disease Neuroimaging Initiative, Urban and Regional Aboriginal Australians, Urban and Rural Areas of China, Worldwide Alzheimer's Disease Neuroimaging Initiative
|
Leave a comment
Faintest Hints of Promise From a Recent Dementia Drug Trial? (BBC News / Alzheimer’s Association International Conference)
Summary Data from a recent trial involving 891 patients, presented at the Alzheimer’s Association International Conference in Toronto this week, indicates that an experimental new drug (LMTX) appears to slow the death of brain cells and preserve mental function in … Continue reading →
Posted in Alzheimer’s Disease International (ADI), BBC News, Charitable Bodies, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Models of Dementia Care, Pharmacological Treatments, Quick Insights, Universal Interest
|
Tagged Abnormal Proteins (Tau), Alzheimer Disease and Related Disorders Research Unit of the McGill University Research Centre for Studies in Aging (Douglas Mental Health University Institute), Alzheimer's Disease Research Unit: McGill University (Canada), Alzheimer’s Association, Alzheimer’s Association International Conference® (AAIC®) 2016, BBC Health News, Degenerative Tauopathy, Dementia Research, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Douglas Mental Health University Institute: McGill University Research Centre for Studies in Aging, Dr Serge Gauthier: Director of Alzheimer's Disease Research Unit at McGill University in Canada, Drug Development for Alzheimer's Disease, Drug Discovery Programmes, Drug Identification, Drug Trials, Drug Trials Failure Rate, Drug-Development Pipeline, Drugs for Treatment of Alzheimer’s Disease, Global Dementia Research, Leuco-methylthioninium-bis (hydromethanesulfonate) (LMTM), Leucomethylthioninium Salts (LMTX), LMTM Monotherapy, LMTX, Ltd., Neurodegeneration, Neurodegenerative Disease Research, Research and Development, Research and Innovation, Research Commitment, Tau, Tau Aggregation, Tau Aggregation Inhibitor Therapy, Tau Aggregation Inhibitors, Tau Pathology, Tau Tangles, Tau-Targeting Drugs, Tauopathy, TauRX, TauRx Therapeutics, Treatment and Prevention of Dementia
|
Leave a comment
European Medicines Agency Consultation on Pharmacological Treatments for Dementia (EMA)
Summary The European Medicines Agency (EMA) has released an updated draft guideline on medicines for the treatment of Alzheimer’s Disease and other types of dementia, for consultative feedback. Full Text Link Reference Consultation on revised guideline on medicines to treat … Continue reading →
Posted in Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), International, Management of Condition, Mental Health, Models of Dementia Care, Pharmacological Treatments, Quick Insights, Standards
|
Tagged Accelerating Alzheimer's Research and Drug Development, Alzheimer’s Disease Biomarkers, Behavioural and Psychiatric Symptoms of Dementia, Behavioural and Psychological Symptoms of Dementia (BPSD), Biomarker Assessments in Alzheimer’s Disease, Biomarker Assessments in Alzheimer’s Disease Clinical Trials, Biomarker Assessments in Clinical Trials, Biomarker Development, Biomarkers, Biomarkers Predicting Cognitive Decline and Alzheimer's Disease, Blood Proteins as Biomarkers of Disease Research, Blood-Based Biomarkers of Pre-Symptomatic Alzheimer’s Disease, BPSD: Behavioral and Psychological Symptoms of Dementia, Cardiovascular Adverse Events, Clinical Diagnostic Criteria, Committee for Medicinal Products for Human Use (CHMP), Comparison IWG and NIA-AA Criteria for Clinical Diagnosis of Alzheimer´s Disease, Diagnostic Tests, Disease Modifying Treatment by 2025 (Aim), Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Drug Development for Alzheimer's Disease, Drug Discovery Programmes, Drug Identification, Drug Target Validation, Drug-Development Pipeline, Drugs for Treatment of Alzheimer’s Disease, Early Detection of Preclinical Disease, Early Diagnosis, Early Diagnosis of Alzheimer's Disease, Early Diagnostic Criteria, EMA Central Nervous System Working Party, EMA: European Medicines Agency, Enrichment of Study Populations, European Medicines Agency, European Medicines Agency (EMA), Genetic Testing, Genetic Triggers, Genetics of Alzheimer's Disease, Guideline on Clinical Investigation of Medicines for Alzheimer’s Disease and Other Dementias, Guideline on Medicinal Products for the Treatment of Alzheimer’s Disease and Nine Other Dementias, International Organisations, International Programmes, International Working Group (IWG), Long-Term Efficacy and Safety Studies, Medical Research, Medicines Development, Medicines Mechanism of Action, National Institutes of Health (NIH), Neurodegeneration, Neurodegenerative Disease Research, Neurodegenerative Diseases, Neurological Adverse Events, Neurological Disorders, Novel Targets in Neurodegeneration, Ordering of Alzheimer's Disease Biomarkers, Pharmaceutical Industry, Pharmacological Research, Preclinical Alzheimer's Disease, Preclinical Biomarkers in Alzheimer's Disease, Preclinical Indicators and Dementia, Preclinical Indicators in Alzheimer's Disease, Prodromal Alzheimer's Disease, Psychiatric Adverse Events, Research and Development, Research and Innovation, Research Commitment, Research Consortia, Research Culture, Research Networks, Research Programmes, Safety and Efficacy Markers, Stratification of Subgroups (Clinical Trials), Target Discovery and Preclinical Validation, Therapeutic Target(s): Identification, Timely Diagnosis
|
Leave a comment
World Alzheimer’s Day (BBC News / ARUK / OHE / NHS Choices)
Summary To mark World Alzheimer’s Day, life-expectancy and dementia incidence statistics, commissioned from the Office of Health Economics, have been used to arrive at the projection that perhaps one in three people born in the UK this year could develop … Continue reading →
Posted in Alzheimer’s Research UK, BBC News, Charitable Bodies, Commissioning, For Carers (mostly), For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), For Social Workers (mostly), In the News, Management of Condition, Models of Dementia Care, NHS Digital (Previously NHS Choices), Patient Care Pathway, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest
|
Tagged Accelerating Alzheimer's Research and Drug Development, Ageing Population, Ageing Society, Alzheimer’s Research UK (ARUK), ARUK: Alzheimer’s Research UK, Behind the Headlines, CFAS I Study, Cognitive Functioning and Ageing Study (CFAS), Costs of Dementia in UK, Delaying Onset: Cost Impact, Delaying Onset: Human Impact, Dementia Innovation, Dementia Research, Dementia Research Champions Group, Disease Modifying Treatment by 2025 (Aim), Disease Progression, Disease-Modifying Therapies, Disease-Modifying Therapies for Dementia, Dr Matthew Norton: Alzheimer's Research UK, Drug Development for Alzheimer's Disease, Drug-Development Pipeline, Epidemiology, Estimation of Future Cases of Dementia: From Males / Females Born in 2015, Forecasting Life Expectancy, Gender (Sex), Gender Differences in Diagnosis Rates, Incidence Studies, Life Expectancy, Life Table Data, Life Tables, National Life Tables, Office of Health Economics (OHE), OHE Consulting, OHE: Office of Health Economics, Prevalence, Prevalence of Dementia, Progression to Alzheimer's Disease, Slowing Progression: Cost Impact, Slowing Progression: Human Impact, Solanezumab (Eli Lilly), Trajectory of Dementia in the UK
|
Leave a comment
New Hopes for Disease-Modifying Pharmacological Dementia Treatment (BBC News / AAIC / ARUK)
Summary Trials of the drug Solanezumab were abandoned in apparent failure in 2012. More detailed examination of the data has since revealed evidence that this medication may have a role in slowing the pace of progression in Alzheimer’s Disease slightly, … Continue reading →
Posted in Alzheimer’s Research UK, BBC News, Charitable Bodies, Diagnosis, For Doctors (mostly), For Nurses and Therapists (mostly), For Researchers (mostly), In the News, International, Management of Condition, Models of Dementia Care, Patient Care Pathway, Pharmacological Treatments, Quick Insights, Statistics, UK, Universal Interest
|
Tagged Accelerating Alzheimer's Research and Drug Development, Alzheimer's Association International Conference (Washington, Alzheimer’s Association International Conference® (AAIC®) 2015, Alzheimer’s Research UK (ARUK), Amyloid, Amyloid Beta, Amyloid Beta Protein, Amyloid Proteins, Amyloid-β (Aβ), Amyloid-β (Aβ) Accumulation, ARUK: Alzheimer’s Research UK, BBC Health News, Big Pharma, Delaying Onset: Cost Impact, Delaying Onset: Human Impact, Disease Modifying Treatment by 2025 (Aim), Disease Progression, Disease-Modifying Therapies for Dementia, Dr Eric Karran: Director of Research at Alzheimer’s Research UK, Drug Development for Alzheimer's Disease, Drug-Development Pipeline, Eli Lilly, EXPEDITION Studies, β-amyloid, July 2015), Misfolded Proteins, Neurofibrillary Tangles, Neuronal Loss, Progression of Mild Cognitive Impairment to Dementia, Progression to Alzheimer's Disease, Slowing Progression: Cost Impact, Slowing Progression: Human Impact, Solanezumab (Eli Lilly), Solanezumab EXPEDITION Trials, Solanezumab for Mild-to-Moderate Alzheimer’s Disease, Solanezumab Trials, Solanezumab: Humanised Monoclonal Antibody
|
Leave a comment
